David Tomazic
Family Medicine · Forest City, PANPI 1912992751
Payments from drug & device makers
Across 459 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$888
- Lilly USA, LLC$725
- GSK$574
- Boehringer Ingelheim$535
- Pfizer$383
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,28499%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,343 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 934 | $309,476 |
| JardianceEmpagliflozin | 202 | $131,238 |
| OxycontinOxycodone Hcl | 13 | $102,639 |
| OzempicSemaglutide | 77 | $72,744 |
| JanuviaSitagliptin Phosphate | 213 | $67,340 |
| MyrbetriqMirabegron | 212 | $51,075 |
| RoxicodoneOxycodone Hcl | 13 | $46,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $41,702 |
| XareltoRivaroxaban | 75 | $38,673 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $31,232 |
| ProvigilModafinil | 13 | $29,575 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $27,667 |
| TradjentaLinagliptin | 62 | $27,158 |
| RexultiBrexpiprazole | 45 | $24,352 |
| EntrestoSacubitril/Valsartan | 66 | $23,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $383 | $309,476934 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $535 | $164,421275 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $574 | $97,433161 claims |
| Novo NordiskOzempic, Rybelsus | $1,176 | $88,41892 claims |
| MerckJanuvia | $172 | $67,340213 claims |
| Astellas Pharma US IncMyrbetriq | $203 | $51,075212 claims |
| Johnson & JohnsonXarelto, Invokana | $180 | $49,47489 claims |
| AstraZenecaBreztri Aerosphere | $888 | $31,23229 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $326 | $24,35245 claims |
| NovartisEntresto | $108 | $23,58566 claims |
| Lilly USA, LLCTrulicity | $725 | $20,41716 claims |
| AbbVieLinzess | $133 | $18,34033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Forest City
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.